Stockreport

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advanci [Read more]